Literature DB >> 21548843

The redesigned follitropin α pen injector for infertility treatment.

Michel Christen1, Joan C Schertz, Pablo Arriagada, Joachim Keitel, Heiko Müller.   

Abstract

INTRODUCTION: Treatment for infertility may require multiple drugs and complex dosing schedules. Available injection devices for patients who require regular injections during treatment are reviewed in this article, focusing on pen injectors used to self-administer recombinant human follicle-stimulating hormone (follitropin α). Following the introduction of the first and second follitropin α pen injectors in the last decade, a third pen injector with improved design for the administration of follitropin α has been developed for use in fertility treatment cycles. AREAS COVERED: This paper presents the results of the dose accuracy testing with this pen injector that was performed in accordance with international standards (EN ISO 11608-1:2000). This overview also provides an understanding of the key features of the redesigned pen injector that are of interest to healthcare professionals. EXPERT OPINION: The availability of an improved injection device for the delivery of follitropin α used during infertility treatment cycles of ovulation induction and assisted reproductive technology offers patients and healthcare professionals new treatment administration options. As fertility treatment cycles involve the use of several injectable gonadotropins, a standard device that could be used for all such treatments would simplify both the administration and the teaching of administration considerably.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21548843     DOI: 10.1517/17425247.2011.581658

Source DB:  PubMed          Journal:  Expert Opin Drug Deliv        ISSN: 1742-5247            Impact factor:   6.648


  7 in total

1.  A redesigned follitropin alfa pen injector for infertility: results of a market research study.

Authors:  Carole Abbotts; Cristiana Salgado-Braga; Céline Audibert-Gros
Journal:  Patient Prefer Adherence       Date:  2011-06-28       Impact factor: 2.711

2.  Multicenter, noninterventional, post-marketing surveillance study to evaluate dosing of recombinant human follicle-stimulating hormone using the redesigned follitropin alfa pen in women undergoing ovulation induction.

Authors:  Frank Nawroth; Andreas Tandler-Schneider; Wilma Bilger
Journal:  Drug Healthc Patient Saf       Date:  2015-04-15

3.  Human factors engineering and design validation for the redesigned follitropin alfa pen injection device.

Authors:  Mary C Mahony; Patricia Patterson; Brooke Hayward; Robert North; Dawne Green
Journal:  Expert Opin Drug Deliv       Date:  2015-05       Impact factor: 6.648

4.  Managing infertility with the follitropin alfa prefilled pen injector - patient considerations.

Authors:  Klaus Bühler
Journal:  Ther Clin Risk Manag       Date:  2015-06-29       Impact factor: 2.423

Review 5.  Gonadotropin therapy in assisted reproduction: an evolutionary perspective from biologics to biotech.

Authors:  Rogério de Barros F Leão; Sandro C Esteves
Journal:  Clinics (Sao Paulo)       Date:  2014       Impact factor: 2.365

Review 6.  Application of Sol-Gels for Treatment of Gynaecological Conditions-Physiological Perspectives and Emerging Concepts in Intravaginal Drug Delivery.

Authors:  Ritu Thapa; Shila Gurung; Marie-Odile Parat; Harendra S Parekh; Preeti Pandey
Journal:  Gels       Date:  2022-02-08

7.  Single-arm, observational study of the ease of use of a redesigned pen device to deliver recombinant human follicle-stimulating hormone (follitropin alfa) for assisted reproductive technology treatment.

Authors:  Peter J Illingworth; Robert Lahoud; Frank Quinn; Kendal Chidwick; Claire Wilkinson; Gavin Sacks
Journal:  Patient Prefer Adherence       Date:  2014-06-05       Impact factor: 2.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.